{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:59:22Z","timestamp":1784908762312,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T00:00:00Z","timestamp":1546560000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00431-018-03310-7","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T05:32:14Z","timestamp":1546579934000},"page":"131-138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["New therapies for acute RSV infections: where are we?"],"prefix":"10.1007","volume":"178","author":[{"given":"Ying","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5576-9517","authenticated-orcid":false,"given":"Marijke","family":"Proesmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,4]]},"reference":[{"issue":"6","key":"3310_CR1","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3201\/eid2006.131438","volume":"20","author":"CN Agoti","year":"2014","unstructured":"Agoti CN, Otieno JR, Gitahi CW, Cane PA, Nokes DJ (2014) Rapid spread and diversification of respiratory syncytial virus genotype ON1, Kenya. Emerg Infect Dis 20(6):950\u2013959","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"3310_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/jcp.23.1.7","volume":"23","author":"W Aherne","year":"1970","unstructured":"Aherne W, Bird T, Court SD, Gardner PS, McQuillin J (1970) Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol 23(1):7\u201318","journal-title":"J Clin Pathol"},{"key":"3310_CR3","unstructured":"Alnylam Pharmaceuticals Inc. (2005) Alnylam initiates phase i clinical study of ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. [cited 2017 November 15]. Available from: http:\/\/investors.alnylam.com\/news-releases\/news-release-details\/alnylam-initiates-phase-i-clinical-study-aln-rsv01-rnai"},{"key":"3310_CR4","unstructured":"Ark Biosciences Inc. (2015) Ark biosciences\u2019 anti-RSV AK0529 successfully completes phase I study. [cited 2017 November 17]. Available from: http:\/\/www.arkbiosciences.com\/index.php?g=&m=article&a=index&id=17&cid=12"},{"issue":"2","key":"3310_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nchembio.1982","volume":"12","author":"MB Battles","year":"2016","unstructured":"Battles MB, Langedijk JP, Furmanova-Hollenstein P, Chaiwatpongsakorn S, Costello HM, Kwanten L, Vranckx L, Vink P, Jaensch S, Jonckers THM, Koul A, Arnoult E, Peeples ME, Roymans D, McLellan JS (2016) Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nat Chem Biol 12(2):87\u201393","journal-title":"Nat Chem Biol"},{"issue":"1","key":"3310_CR6","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1542\/peds.2014-2151","volume":"135","author":"CL Byington","year":"2015","unstructured":"Byington CL, Wilkes J, Korgenski K, Sheng X (2015) Respiratory syncytial virus-associated mortality in hospitalized infants and young children. Pediatrics 135(1):e24\u2013e31","journal-title":"Pediatrics"},{"issue":"3","key":"3310_CR7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1017\/S0950268805005571","volume":"134","author":"G Cilla","year":"2006","unstructured":"Cilla G, Sarasua A, Montes M, Arostegui N, Vicente D, P\u00e9rez-Yarza E et al (2006) Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain. Epidemiol Infect 134(3):506\u2013513","journal-title":"Epidemiol Infect"},{"key":"3310_CR8","unstructured":"Depla E. (2014) Ablynx: Development of ALX-0171, an inhaled Nanobody \u00ae for the treatment of respiratory syncytial virus infection in infants. [cited 2017 November 1]; Available from: http:\/\/www.ablynx.com\/uploads\/data\/files\/rsv_hah-2014.pdf"},{"key":"3310_CR9","unstructured":"Depla E. (2015) Ablynx: ALX-0171: safety, efficacy and therapeutic potential of an inhaled anti-RSV Nanobody. [cited 2017 November 1]; Available from: http:\/\/www.ablynx.com\/uploads\/data\/files\/alx-0171rddconferencemay2015.pdf"},{"issue":"1","key":"3310_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1128\/AAC.01802-15","volume":"60","author":"L Detalle","year":"2016","unstructured":"Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, Melero JA, Depla E (2016) Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob Agents Chemother 60(1):6\u201313","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"3310_CR11","doi-asserted-by":"publisher","first-page":"1004995","DOI":"10.1371\/journal.ppat.1004995","volume":"11","author":"J Deval","year":"2015","unstructured":"Deval J, Hong J, Wang G, Taylor J, Smith LK, Fung A et al (2015) Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2\u2019-fluoro-4\u2019-chloromethyl-cytidine triphosphate. PLoS Pathog 11(6):1004995","journal-title":"PLoS Pathog"},{"issue":"3","key":"3310_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.antiviral.2007.11.009","volume":"77","author":"J DeVincenzo","year":"2008","unstructured":"DeVincenzo J, Cehelsky JE, Alvarez R, Elbashir S, Harborth J, Toudjarska I, Nechev L, Murugaiah V, van Vliet A, Vaishnaw AK, Meyers R (2008) Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antivir Res 77(3):225\u2013231","journal-title":"Antivir Res"},{"issue":"19","key":"3310_CR13","doi-asserted-by":"publisher","first-page":"8800","DOI":"10.1073\/pnas.0912186107","volume":"107","author":"J DeVincenzo","year":"2010","unstructured":"DeVincenzo J, Lambkin-Williams R, Wilkinson T, Cehelsky J, Nochur S, Walsh E, Meyers R, Gollob J, Vaishnaw A (2010) A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A 107(19):8800\u20138805","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"3310_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1401184","volume":"371","author":"JP DeVincenzo","year":"2014","unstructured":"DeVincenzo JP, Whitley RJ, Mackman RL, Scaglioni-Weinlich C, Harrison L, Farrell E et al (2014) Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 371(8):711\u2013722","journal-title":"N Engl J Med"},{"issue":"21","key":"3310_CR15","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/NEJMoa1413275","volume":"373","author":"JP DeVincenzo","year":"2015","unstructured":"DeVincenzo JP, McClure MW, Symons JA, Fathi H, Westland C, Chanda S et al (2015) Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med 373(21):2048\u20132058","journal-title":"N Engl J Med"},{"issue":"9","key":"3310_CR16","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.1128\/JVI.77.9.5054-5064.2003","volume":"77","author":"JL Douglas","year":"2003","unstructured":"Douglas JL, Panis ML, Ho E, Lin KY, Krawczyk SH, Grant DM, Cai R, Swaminathan S, Cihlar T (2003) Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J Virol 77(9):5054\u20135064","journal-title":"J Virol"},{"issue":"2","key":"3310_CR17","doi-asserted-by":"publisher","first-page":"12657","DOI":"10.1111\/tid.12657","volume":"19","author":"AR Falsey","year":"2017","unstructured":"Falsey AR, Koval C, DeVincenzo JP, Walsh EE (2017) Compassionate use experience with high-titer respiratory syncytial virus (RSV) immunoglobulin in RSV-infected immunocompromised persons. Transpl Infect Dis 19(2):12657","journal-title":"Transpl Infect Dis"},{"key":"3310_CR18","unstructured":"Gadomski AM, Scribani MB (2014) \u201cBronchodilators for bronchiolitis\u201d. Cochrane Database Syst Rev Jun 17(6):CD001266"},{"key":"3310_CR19","unstructured":"Glanville A, Musk M, Zamora M, Hodges T, Arcasoy S, Sommerwerck U, Alnylam Pharmaceuticals Inc. et al. (2012) Results of a phase 2b multi-center, randomized, double-blind, placebo-controlled study of an RNAi therapeutic, ALN-RSV01, in respiratory syncytial virus (RSV)-infected lung transplant patients. [cited 2017 November 15]. Available from: http:\/\/www.alnylam.com\/web\/assets\/RSV01-109-ERS-Oral-Final-24Aug2012.pdf"},{"issue":"6","key":"3310_CR20","first-page":"543","volume":"140","author":"WP Glezen","year":"1986","unstructured":"Glezen WP, Taber LH, Frank AL, Kasel JA (1986) Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140(6):543\u2013546","journal-title":"Am J Dis Child"},{"issue":"4","key":"3310_CR21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jama.283.4.499","volume":"283","author":"WP Glezen","year":"2000","unstructured":"Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB (2000) Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 283(4):499\u2013505","journal-title":"JAMA"},{"key":"3310_CR22","first-page":"391","volume":"372","author":"BS Graham","year":"2013","unstructured":"Graham BS, Anderson LJ (2013) Challenges and opportunities for respiratory syncytial virus vaccines. Curr Top Microbiol Immunol 372:391\u2013404","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"3310_CR23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1128\/CMR.00010-16","volume":"30","author":"C Griffiths","year":"2017","unstructured":"Griffiths C, Drews SJ, Marchant DJ (2017) Respiratory syncytial virus: infection, detection, and new options for prevention and treatment. Clin Microbiol Rev 30(1):277\u2013319","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"3310_CR24","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1542\/peds.2013-0303","volume":"132","author":"CB Hall","year":"2013","unstructured":"Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, Poehling KA, Szilagyi PG, Griffin MR, Williams JV, Zhu Y, Grijalva CG, Prill MM, Iwane MK (2013) Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics 132(2):e341\u2013e348","journal-title":"Pediatrics"},{"issue":"4","key":"3310_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1046\/j.1469-7580.2002.00097.x","volume":"201","author":"AA Hislop","year":"2002","unstructured":"Hislop AA (2002) Airway and blood vessel interaction during lung development. J Anat 201(4):325\u2013334","journal-title":"J Anat"},{"issue":"11","key":"3310_CR26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s40262-017-0522-8","volume":"56","author":"DRH Huntjens","year":"2017","unstructured":"Huntjens DRH, Ouwerkerk-Mahadevan S, Brochot A, Rusch S, Stevens M, Verloes R (2017) Population pharmacokinetic modeling of JNJ-53718678, a novel fusion inhibitor for the treatment of respiratory syncytial virus: results from a phase I, double-blind, randomized, placebo-controlled first-in-human study in healthy adult subjects. Clin Pharmacokinet 56(11):1331\u20131342","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3310_CR27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1542\/peds.102.3.531","volume":"102","author":"Impact-RSV Study Group","year":"1998","unstructured":"Impact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102(3):531\u2013537","journal-title":"Pediatrics"},{"issue":"Suppl 1","key":"3310_CR28","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/ofid\/ofw172.513","volume":"3","author":"S Israel","year":"2016","unstructured":"Israel S, Rusch S, DeVincenzo J, Boyers A, Fok-Seang J, Huntjens D et al (2016) Effect of oral JNJ-53718678 (JNJ-678) on disease severity in healthy adult volunteers experimentally inoculated with live respiratory syncytial virus (RSV): a placebo-controlled challenge study. Open Forum Infect Dis 3(Suppl 1):650","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"3310_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/modpathol.3800725","volume":"20","author":"JE Johnson","year":"2007","unstructured":"Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS (2007) The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 20(1):108\u2013119","journal-title":"Mod Pathol"},{"issue":"6","key":"3310_CR30","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/irv.12503","volume":"11","author":"YI Kim","year":"2017","unstructured":"Kim YI, Pareek R, Murphy R, Harrison L, Farrell E, Cook R, DeVincenzo J (2017) The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, vs its achievable concentrations in the human respiratory tract and comparison to ribavirin. Influ Other Respir Viruses 11(6):525\u2013530","journal-title":"Influ Other Respir Viruses"},{"issue":"11","key":"3310_CR31","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S2213-2600(15)00255-6","volume":"3","author":"NI Mazur","year":"2015","unstructured":"Mazur NI, Martin\u00f3n-Torres F, Baraldi E, Fauroux B, Greenough A, Heikkinen T, Manzoni P, Mejias A, Nair H, Papadopoulos NG, Polack FP, Ramilo O, Sharland M, Stein R, Madhi SA, Bont L, Respiratory Syncytial Virus Network (ReSViNET) (2015) Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med 3(11):888\u2013900","journal-title":"Lancet Respir Med"},{"issue":"1","key":"3310_CR32","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMra1413456","volume":"374","author":"HC Meissner","year":"2016","unstructured":"Meissner HC (2016) Viral bronchiolitis in children. N Engl J Med 374(1):1793\u20131794","journal-title":"N Engl J Med"},{"issue":"8","key":"3310_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jiac.2014.05.001","volume":"20","author":"M Mori","year":"2014","unstructured":"Mori M, Morio T, Ito S, Morimoto A, Ota S, Mizuta K, Iwata T, Hara T, Saji T (2014) Risks and prevention of severe RS virus infection among children with immunodeficiency and Down\u2019s syndrome. J Infect Chemother 20(8):455\u2013459","journal-title":"J Infect Chemother"},{"issue":"9725","key":"3310_CR34","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","volume":"375","author":"H Nair","year":"2010","unstructured":"Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Sim\u00f5es EAF, Rudan I, Weber MW, Campbell H (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375(9725):1545\u20131555","journal-title":"Lancet"},{"key":"3310_CR35","unstructured":"National Institute for Health and Care Excellence: Bronchiolitis in children: diagnosis and management | Guidance and guidelines | NICE. (2015) [cited 2018 May 24]; Available from: https:\/\/www.nice.org.uk\/guidance\/NG9"},{"key":"3310_CR36","first-page":"5743","volume":"2014","author":"S Ostadabbas","year":"2014","unstructured":"Ostadabbas S, Bulach C, Ku DN, Anderson LJ, Ghovanloo M (2014) A passive quantitative measurement of airway resistance using depth data. Conf Proc IEEE Eng Med Biol Soc 2014:5743\u20135747","journal-title":"Conf Proc IEEE Eng Med Biol Soc"},{"issue":"3","key":"3310_CR37","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1128\/AAC.01497-15","volume":"60","author":"M Perron","year":"2015","unstructured":"Perron M, Stray K, Kinkade A, Theodore D, Lee G, Eisenberg E, Sangi M, Gilbert BE, Jordan R, Piedra PA, Toms GL, Mackman R, Cihlar T (2015) GS-5806 inhibits a broad range of respiratory syncytial virus clinical isolates by blocking the virus-cell fusion process. Antimicrob Agents Chemother 60(3):1264\u20131273","journal-title":"Antimicrob Agents Chemother"},{"key":"3310_CR38","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1542\/peds.2014-2742","volume":"134","author":"SL Ralston","year":"2014","unstructured":"Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, and the American Academy of Pediatrics et al (2014) Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics 134:1474\u20131502","journal-title":"Pediatrics"},{"issue":"11,Suppl 12","key":"3310_CR39","first-page":"13","volume":"17","author":"JA Ramirez","year":"2008","unstructured":"Ramirez JA (2008) RSV infection in the adult population. Manag Care 17(11,Suppl 12):13\u201315 discussion 18-9","journal-title":"Manag Care"},{"issue":"8","key":"3310_CR40","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/INF.0b013e31829061e8","volume":"32","author":"SA R\u00e9gnier","year":"2013","unstructured":"R\u00e9gnier SA, Huels J (2013) Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae: systematic review and meta-analysis. Pediatr Infect Dis J 32(8):820\u2013826","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"3310_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41467-017-00170-x","volume":"8","author":"D Roymans","year":"2017","unstructured":"Roymans D, Alnajjar SS, Battles MB, Sitthicharoenchai P, Furmanova-Hollenstein P, Rigaux P, Berg JV, Kwanten L, Ginderen MV, Verheyen N, Vranckx L, Jaensch S, Arnoult E, Voorzaat R, Gallup JM, Larios-Mora A, Crabbe M, Huntjens D, Raboisson P, Langedijk JP, Ackermann MR, McLellan JS, Vendeville S, Koul A (2017) Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nat Commun 8(1):167","journal-title":"Nat Commun"},{"issue":"11","key":"3310_CR42","doi-asserted-by":"publisher","first-page":"7109","DOI":"10.1128\/AAC.00761-15","volume":"59","author":"D Samuel","year":"2015","unstructured":"Samuel D, Xing W, Niedziela-Majka A, Wong JS, Hung M, Brendza KM, Perron M, Jordan R, Sperandio D, Liu X, Mackman R, Sakowicz R (2015) GS-5806 inhibits pre- to postfusion conformational changes of the respiratory syncytial virus fusion protein. Antimicrob Agents Chemother 59(11):7109\u20137112","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"3310_CR43","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/adc.76.3.210","volume":"76","author":"RL Smyth","year":"1997","unstructured":"Smyth RL, Fletcher JN, Thomas HM, Hart CA (1997) Immunological responses to respiratory syncytial virus infection in infancy. Arch Dis Child 76(3):210\u2013214","journal-title":"Arch Dis Child"},{"issue":"1","key":"3310_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.13.1.1","volume":"13","author":"WM Sullender","year":"2000","unstructured":"Sullender WM (2000) Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol Rev 13(1):1\u201315","journal-title":"Clin Microbiol Rev"},{"issue":"10","key":"3310_CR45","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s10096-018-3289-4","volume":"37","author":"SA Taleb","year":"2018","unstructured":"Taleb SA, Al Thani AA, Al Ansari K, Yassine HM (2018) Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches. Eur J Clin Microbiol Infect Dis 37(10):1817\u20131827","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"3310_CR46","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2174\/187152612800100116","volume":"12","author":"EE Walsh","year":"2012","unstructured":"Walsh EE, Falsey AR (2012) Respiratory syncytial virus infection in adult populations. Infect Disord Drug Targets 12(2):98\u2013102","journal-title":"Infect Disord Drug Targets"},{"issue":"4","key":"3310_CR47","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1021\/jm5017279","volume":"58","author":"G Wang","year":"2015","unstructured":"Wang G, Deval J, Hong J, Dyatkina N, Prhavc M, Taylor J, Fung A, Jin Z, Stevens SK, Serebryany V, Liu J, Zhang Q, Tam Y, Chanda SM, Smith DB, Symons JA, Blatt LM, Beigelman L (2015) Discovery of 4\u2019-chloromethyl-2\u2019-deoxy-3\u2019,5\u2019-di-O-isobutyryl-2\u2019-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem 58(4):1862\u20131878","journal-title":"J Med Chem"},{"issue":"4","key":"3310_CR48","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1164\/rccm.201003-0422OC","volume":"183","author":"MR Zamora","year":"2011","unstructured":"Zamora MR, Budev M, Rolfe M, Gottlieb J, Humar A, Devincenzo J et al (2011) RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 183(4):531\u2013538","journal-title":"Am J Respir Crit Care Med"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00431-018-03310-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-018-03310-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-018-03310-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T18:07:29Z","timestamp":1662746849000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00431-018-03310-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,4]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["3310"],"URL":"https:\/\/doi.org\/10.1007\/s00431-018-03310-7","relation":{},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"value":"0340-6199","type":"print"},{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,4]]},"assertion":[{"value":"13 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical statements"}},{"value":"Ying Xing has no conflict of interest to declare. Marijke\u00a0Proesmans is the principal investigator for the drugs JNJ-53718678 and ALX-0171.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study: not applicable for this type of manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}